Anzeige
Mehr »
Login
Sonntag, 20.06.2021 Börsentäglich über 12.000 News von 662 internationalen Medien
Diese POWER-AKTIE trotzt allem und steigt einfach weiter! Ausbruch unter hohem Volumen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 924801 ISIN: US09061G1013 Ticker-Symbol: BM8 
Tradegate
18.06.21
19:00 Uhr
68,80 Euro
-0,92
-1,32 %
1-Jahres-Chart
BIOMARIN PHARMACEUTICAL INC Chart 1 Jahr
5-Tage-Chart
BIOMARIN PHARMACEUTICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
67,2670,8818.06.
68,8469,2418.06.

Aktuelle News zur BIOMARIN PHARMACEUTICAL Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
02.06.Here's Why ClearBridge Sold its BioMarin Pharmaceutical (BMRN) Position23
02.06.BioMarin: Too Soon To Buy14
01.06.BIOMARIN PHARMACEUTICAL INC - 8-K, Current Report3
BIOMARIN PHARMACEUTICAL Aktie jetzt für 0€ handeln
25.05.BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review16
24.05.EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy2
24.05.Verastem wins breakthrough nod for combo therapy in ovarian cancer; EMA picks up speedy review of BioMarin's gene therapy10
24.05.BioMarin: EMA Grants Accelerated Assessment For Review Of Valoctocogene Roxaparvovec422WASHINGTON (dpa-AFX) - The European Medicines Agency or EMA has granted its request for accelerated assessment of valoctocogene roxaparvovec, for adults with severe hemophilia A, BioMarin Pharmaceutical...
► Artikel lesen
24.05.EMA grants Biomarin's request for accelerated assessment of valoctocogene roxaparvovec in severe hemophilia A3
19.05.Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit7
19.05.BioMarin: Phase 1/2 Study On Hemophilia A Shows Hemostatic Control With Valoctocogene Roxaparvovec328WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN), in an update on phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia...
► Artikel lesen
19.05.BioMarin reports five-year data from mid-stage gene therapy study in hemophilia A1
04.05.BioMarin's CEO Bienaime, in his 16th year at the helm, scores $18M pay package8
30.04.BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q1 2021 Results - Earnings Call Transcript12
29.04.PDUFA date for BioMarin's vosoritide extended by three months9
29.04.Biomarin Pharmaceutical: Q1 Earnings Insights9
29.04.Biomarin Pharmaceutical Inc. Reports Retreat In Q1 Profit300WASHINGTON (dpa-AFX) - Biomarin Pharmaceutical Inc. (BMRN) revealed earnings for first quarter that declined from the same period last year.The company's earnings came in at $17.37 million,...
► Artikel lesen
29.04.BIOMARIN PHARMACEUTICAL INC - 8-K, Current Report1
28.04.Allen Institute, BioMarin To Develop Gene Therapies For Rare Brain Diseases369WASHINGTON (dpa-AFX) - The Allen Institute and BioMarin Pharmaceutical Inc. (BMRN) announced a collaboration today that will use technologies developed at the Allen Institute to create new gene...
► Artikel lesen
28.04.Biomarin and Allen Institute team up to develop gene therapies1
15.04.BioMarin posts positive updated phase 2 data on vosoritide for achondroplasia18
Seite:  Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,4